Humacyte, Inc. (NASDAQ:HUMA) CFO Dale A. Sander Buys 20,000 Shares

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) CFO Dale A. Sander purchased 20,000 shares of the firm's stock in a transaction on Thursday, April 10th. The stock was bought at an average price of $1.53 per share, for a total transaction of $30,600.00. Following the purchase, the chief financial officer now owns 40,600 shares in the company, valued at approximately $62,118. This represents a 97.09 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Humacyte Trading Up 8.4 %

Humacyte stock traded up $0.13 during trading on Friday, hitting $1.68. The company had a trading volume of 3,081,887 shares, compared to its average volume of 3,568,026. The stock has a market cap of $260.60 million, a price-to-earnings ratio of -1.25 and a beta of 1.62. The company's 50 day simple moving average is $2.61 and its 200-day simple moving average is $4.05. Humacyte, Inc. has a 1-year low of $1.15 and a 1-year high of $9.97.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its earnings results on Friday, March 28th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.07. The business had revenue of $7.23 million for the quarter, compared to analysts' expectations of $0.64 million. As a group, analysts forecast that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. HC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Humacyte in a report on Wednesday, March 12th. Benchmark reissued a "buy" rating on shares of Humacyte in a report on Thursday, February 27th. Finally, D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of Humacyte in a report on Wednesday, March 26th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Humacyte presently has an average rating of "Buy" and an average target price of $13.71.

Institutional Investors Weigh In On Humacyte

Several large investors have recently modified their holdings of the company. Woodline Partners LP boosted its stake in shares of Humacyte by 235.7% during the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company's stock worth $14,386,000 after buying an additional 2,000,268 shares during the period. State Street Corp raised its position in Humacyte by 66.1% during the third quarter. State Street Corp now owns 4,764,155 shares of the company's stock worth $25,917,000 after acquiring an additional 1,895,529 shares during the last quarter. CenterBook Partners LP acquired a new stake in Humacyte during the 4th quarter valued at $6,463,000. Brevan Howard Capital Management LP increased its position in Humacyte by 2,795.1% during the 4th quarter. Brevan Howard Capital Management LP now owns 876,340 shares of the company's stock worth $4,426,000 after purchasing an additional 846,070 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock worth $28,294,000 after buying an additional 543,995 shares in the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.